ADVENTRX PHARMA WKN: A2DQ2B ISIN: US8051111016 Kürzel: YB4P Forum: Aktien Thema: Hauptdiskussion

Savara Inc. (Nasdaq: SVRA) announced that the FDA granted Breakthrough Therapy designation for Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The Breakthrough Therapy designation is based on data from IMPALA, a Phase 3 trial evaluating Molgradex for the treatment of aPAP, which failed to meet its primary endpoint in June last year. Shares closed the week up 133% to $4.07.

Rebound Kandidat und günstig bewertet.🧐 Savara Inc. (Nasdaq: SVRA) shares slid to close the week down 67% to $0.93 following news that the FDA has advised the company not to submit a Biologics License Application (BLA) for its pipeline candidate Molgradex, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) due to insufficient evidence of efficacy and safety MK 40Mio$ Cash ca. 110Mio$ Cash Burn: 4.3Mio/month

Läuft.

..

Erster